JP2023550543A - 二環式化合物及び疾患の治療のためのその使用 - Google Patents

二環式化合物及び疾患の治療のためのその使用 Download PDF

Info

Publication number
JP2023550543A
JP2023550543A JP2023551946A JP2023551946A JP2023550543A JP 2023550543 A JP2023550543 A JP 2023550543A JP 2023551946 A JP2023551946 A JP 2023551946A JP 2023551946 A JP2023551946 A JP 2023551946A JP 2023550543 A JP2023550543 A JP 2023550543A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550543A5 (https=
Inventor
リーン カワス
ケビン チャーチ
ロバート テイラー
ジュエル ジョンストン
ダグラス ボートマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athira Pharma Inc
Original Assignee
Athira Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athira Pharma Inc filed Critical Athira Pharma Inc
Publication of JP2023550543A publication Critical patent/JP2023550543A/ja
Publication of JP2023550543A5 publication Critical patent/JP2023550543A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023551946A 2020-11-02 2021-11-01 二環式化合物及び疾患の治療のためのその使用 Pending JP2023550543A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108660P 2020-11-02 2020-11-02
US63/108,660 2020-11-02
PCT/US2021/057563 WO2022094400A1 (en) 2020-11-02 2021-11-01 Bicyclic compounds and uses thereof for the treatment of diseases

Publications (2)

Publication Number Publication Date
JP2023550543A true JP2023550543A (ja) 2023-12-01
JP2023550543A5 JP2023550543A5 (https=) 2024-11-06

Family

ID=81384389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551946A Pending JP2023550543A (ja) 2020-11-02 2021-11-01 二環式化合物及び疾患の治療のためのその使用

Country Status (12)

Country Link
US (1) US20240025903A1 (https=)
EP (1) EP4236944A4 (https=)
JP (1) JP2023550543A (https=)
KR (1) KR20230104191A (https=)
CN (2) CN119684295A (https=)
AR (1) AR124637A1 (https=)
AU (1) AU2021371026A1 (https=)
CA (1) CA3196582A1 (https=)
CL (2) CL2023001195A1 (https=)
IL (1) IL302465A (https=)
MX (1) MX2023004942A (https=)
WO (1) WO2022094400A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240121239A (ko) * 2021-12-17 2024-08-08 아티라 파마, 인코포레이티드 질환 치료를 위한 이환식 화합물의 용도
EP4518864A1 (en) * 2022-05-04 2025-03-12 Athira Pharma, Inc. Methods of treating neuropathies
JP2025515045A (ja) * 2022-05-04 2025-05-13 アティラ・ファーマ・インコーポレイテッド 神経炎症病態を治療する方法
EP4618996A1 (en) 2022-11-18 2025-09-24 Athira Pharma, Inc. Methods of treating inflammatory conditions

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503352A (ja) * 1999-06-25 2003-01-28 モレキュメティックス リミテッド 逆ターン模倣物およびそれに関する方法
WO2004035587A1 (en) * 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
JP2006513221A (ja) * 2002-12-21 2006-04-20 アンジオン バイオメディカ コーポレイション 肝細胞増殖因子（分散因子）活性のピラゾール誘導体モジュレーター
JP2008514636A (ja) * 2004-09-28 2008-05-08 アンジオン バイオメディカ コーポレイション サイトカイン活性の低分子モジュレーター
US7879898B1 (en) * 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
JP2012505153A (ja) * 2008-10-14 2012-03-01 ＰＲＩＳＭ ＢｉｏＬａｂ株式会社 アルファへリックスミメティック及び関連の方法
WO2014025832A1 (en) * 2012-08-06 2014-02-13 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
WO2017047762A1 (ja) * 2015-09-18 2017-03-23 国立大学法人鳥取大学 低分子化合物による癌と線維化の抑制と再生促進の効果

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503352A (ja) * 1999-06-25 2003-01-28 モレキュメティックス リミテッド 逆ターン模倣物およびそれに関する方法
WO2004035587A1 (en) * 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
JP2006513221A (ja) * 2002-12-21 2006-04-20 アンジオン バイオメディカ コーポレイション 肝細胞増殖因子（分散因子）活性のピラゾール誘導体モジュレーター
JP2008514636A (ja) * 2004-09-28 2008-05-08 アンジオン バイオメディカ コーポレイション サイトカイン活性の低分子モジュレーター
US7879898B1 (en) * 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
JP2012505153A (ja) * 2008-10-14 2012-03-01 ＰＲＩＳＭ ＢｉｏＬａｂ株式会社 アルファへリックスミメティック及び関連の方法
WO2014025832A1 (en) * 2012-08-06 2014-02-13 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
WO2017047762A1 (ja) * 2015-09-18 2017-03-23 国立大学法人鳥取大学 低分子化合物による癌と線維化の抑制と再生促進の効果

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIN-WOONG, KIM ET AL.: "Solution-phase Synthesis and Preliminary Evaluation of 1,6,8-Trisubstituted Tetrahydro-2H-pyrazino[1", BULL. KOREAN CHEM. SOC., vol. 27, no. 12, JPN6025035453, 2006, pages 2087 - 2090, ISSN: 0005678210 *

Also Published As

Publication number Publication date
EP4236944A4 (en) 2024-09-04
TW202233622A (zh) 2022-09-01
US20240025903A1 (en) 2024-01-25
WO2022094400A1 (en) 2022-05-05
MX2023004942A (es) 2023-07-06
EP4236944A1 (en) 2023-09-06
CA3196582A1 (en) 2022-05-05
AR124637A1 (es) 2023-04-19
CN116568301A (zh) 2023-08-08
CL2023001195A1 (es) 2023-10-20
AU2021371026A9 (en) 2024-04-18
KR20230104191A (ko) 2023-07-07
IL302465A (en) 2023-06-01
CL2024000340A1 (es) 2024-08-16
CN119684295A (zh) 2025-03-25
AU2021371026A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
JP2023550543A (ja) 二環式化合物及び疾患の治療のためのその使用
JP2024546600A (ja) 疾患の治療のための二環式化合物の使用
WO2024077057A1 (en) Phenyl oxy amide kinase inhibitors
JP2025515045A (ja) 神経炎症病態を治療する方法
JP2025515047A (ja) 線維症の治療方法
TWI918751B (zh) 用於治療疾病之雙環化合物及其用途
CN118382441A (zh) 双环化合物用于治疗疾病的用途
EA049703B1 (ru) Бициклические соединения и их применение для лечения заболеваний
HK40122844A (zh) 用於治疗疾病的双环化合物及其用途
EA050745B1 (ru) Применение бициклических соединений для лечения заболеваний
HK40097563A (zh) 用於治疗疾病的双环化合物及其用途
JP2025515044A (ja) 神経障害の治療方法
HK40113746A (zh) 双环化合物用於治疗疾病的用途
WO2025250930A1 (en) Hdac6 inhibitors and method of their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230530

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227